NASDAQ:ASRT Assertio (ASRT) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free ASRT Stock Alerts $0.86 -0.05 (-5.30%) (As of 01:56 PM ET) Add Compare Share Share Today's Range$0.85▼$0.9050-Day Range$0.75▼$1.1452-Week Range$0.75▼$8.01Volume481,263 shsAverage Volume1.01 million shsMarket Capitalization$81.93 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Assertio alerts: Email Address Assertio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside538.6% Upside$5.50 Price TargetShort InterestBearish10.91% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$11,481 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.04) to $0.19 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.26 out of 5 starsMedical Sector736th out of 909 stocksPharmaceutical Preparations Industry340th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingAssertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAssertio has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.91% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Assertio has recently decreased by 3.26%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAssertio does not currently pay a dividend.Dividend GrowthAssertio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASRT. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 9 people have searched for ASRT on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assertio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,481.00 in company stock.Percentage Held by InsidersOnly 7.90% of the stock of Assertio is held by insiders.Percentage Held by Institutions48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Assertio are expected to grow in the coming year, from ($0.04) to $0.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assertio is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assertio is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssertio has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Assertio Stock (NASDAQ:ASRT)Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Read More ASRT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASRT Stock News HeadlinesApril 3, 2024 | finance.yahoo.comSig Kirk Joins Assertio Board of DirectorsApril 1, 2024 | globenewswire.comAssertio to Present at LD Micro Invitational Conference in New York CityApril 24, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 14, 2024 | finance.yahoo.comThese Analysts Think Assertio Holdings, Inc.'s (NASDAQ:ASRT) Earnings Are Under ThreatMarch 12, 2024 | finance.yahoo.comAssertio Holdings Inc (ASRT) Reports Mixed Fourth Quarter and Full Year 2023 Financial ResultsMarch 12, 2024 | finanznachrichten.deAssertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 12, 2024 | finance.yahoo.comQ4 2023 Assertio Holdings Inc Earnings CallMarch 12, 2024 | insidermonkey.comAssertio Holdings, Inc. (NASDAQ:ASRT) Q4 2023 Earnings Call TranscriptApril 24, 2024 | DTI (Ad)What is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…March 11, 2024 | benzinga.comRecap: Assertio Holdings Q4 EarningsMarch 11, 2024 | msn.comAssertio Holdings Non-GAAP EPS of $0.11, revenue of $32.99M misses by $0.82MMarch 11, 2024 | sfgate.comAssertio: Q4 Earnings SnapshotMarch 11, 2024 | globenewswire.comAssertio Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 11, 2024 | msn.comSam Altman retorna ao conselho da OpenAI; Coinbase, MicroStrategy sobem no pré-mercado com novo marco do BTC, e maisMarch 11, 2024 | finance.yahoo.comASRT Mar 2024 4.500 callMarch 10, 2024 | msn.comAssertio Holdings Q4 2023 Earnings PreviewMarch 8, 2024 | benzinga.comAssertio Holdings's Earnings: A PreviewMarch 5, 2024 | prnewswire.comThe Gross Law Firm Notifies Assertio Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ASRTMarch 4, 2024 | stockhouse.comAssertio 24 Hour Deadline AlertMarch 4, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)March 3, 2024 | markets.businessinsider.comAssertio 48 Hour Deadline AlertMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Assertio Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - ASRTMarch 1, 2024 | stockhouse.comAssertio Shareholder NoticeFebruary 29, 2024 | finance.yahoo.comAssertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024February 29, 2024 | globenewswire.comAssertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024February 29, 2024 | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AssertioFebruary 28, 2024 | prnewswire.comKessler Topaz Meltzer & Check, LLP Reminds Assertio Holdings, Inc. (ASRT) Investors of March 5, 2024 Lead Plaintiff Deadline and Urges Investors with Substantial Losses to Contact the FirmSee More Headlines Receive ASRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today4/24/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ASRT CUSIPN/A CIK1808665 Webwww.assertiotx.com Phone(224) 419-7106Fax510-744-8001Employees53Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside+538.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-331,940,000.00 Net Margins-218.28% Pretax Margin-167.07% Return on Equity6.30% Return on Assets3.54% Debt Debt-to-Equity Ratio0.28 Current Ratio1.83 Quick Ratio1.43 Sales & Book Value Annual Sales$152.07 million Price / Sales0.54 Cash Flow$0.72 per share Price / Cash Flow1.19 Book Value$1.46 per share Price / Book0.59Miscellaneous Outstanding Shares95,120,000Free Float87,495,000Market Cap$81.93 million OptionableOptionable Beta0.96 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMs. Heather L. Mason (Age 64)Interim CEO & Director Comp: $92.5kMr. Ajay Patel (Age 39)Senior VP & CFO Comp: $742.01kMr. Paul Schwichtenberg (Age 52)Senior Vice President & Chief Commercial Officer Comp: $780.88kMr. Bill IskosSenior Vice President of OperationsMs. Molly DirSenior Vice President of HR & Administration ?Mr. Sam SchlessingerSenior VP & General CounselDr. Howard J. Franklin M.B.A.M.D., Senior Vice President of MedicalMore ExecutivesKey CompetitorsAclaris TherapeuticsNASDAQ:ACRSReviva PharmaceuticalsNASDAQ:RVPHEton PharmaceuticalsNASDAQ:ETONBeyondSpringNASDAQ:BYSIQ32 BioNASDAQ:QTTBView All CompetitorsInsiders & InstitutionsDenali Advisors LLCBought 122,500 shares on 4/19/2024Ownership: 0.174%James L TyreeSold 10,251 sharesTotal: $11,481.12 ($1.12/share)Armistice Capital LLCBought 1,876,000 shares on 2/13/2024Ownership: 6.127%Senvest Management LLCBought 562,898 shares on 2/12/2024Ownership: 0.595%Sargent Investment Group LLCSold 35,682 shares on 2/5/2024Ownership: 0.047%View All Insider TransactionsView All Institutional Transactions ASRT Stock Analysis - Frequently Asked Questions Should I buy or sell Assertio stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASRT shares. View ASRT analyst ratings or view top-rated stocks. What is Assertio's stock price target for 2024? 1 analysts have issued twelve-month price targets for Assertio's stock. Their ASRT share price targets range from $4.00 to $7.00. On average, they expect the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 538.6% from the stock's current price. View analysts price targets for ASRT or view top-rated stocks among Wall Street analysts. How have ASRT shares performed in 2024? Assertio's stock was trading at $1.07 on January 1st, 2024. Since then, ASRT shares have decreased by 19.5% and is now trading at $0.8613. View the best growth stocks for 2024 here. When is Assertio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ASRT earnings forecast. How were Assertio's earnings last quarter? Assertio Holdings, Inc. (NASDAQ:ASRT) announced its quarterly earnings data on Monday, March, 11th. The company reported $0.08 earnings per share for the quarter. The firm earned $32.99 million during the quarter, compared to the consensus estimate of $31.42 million. Assertio had a positive trailing twelve-month return on equity of 6.30% and a negative net margin of 218.28%. What guidance has Assertio issued on next quarter's earnings? Assertio updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $110.0 million-$125.0 million, compared to the consensus revenue estimate of $160.6 million. What other stocks do shareholders of Assertio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK). Who are Assertio's major shareholders? Assertio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Denali Advisors LLC (0.17%). Insiders that own company stock include Ajay Patel, Daniel A Peisert, Heather L Mason, James L Tyree, Paul Schwichtenberg, Sam Schlessinger and William Mckee. View institutional ownership trends. How do I buy shares of Assertio? Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ASRT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
